Introduction
============

Cancer is the most lethal factor in developed countries and the second most lethal factor in developing countries.[@b1-ott-9-1151] According to GLOBOCAN 2012, the number of new cases increased from 12.7 to 14.1 million in 2012, and 8.2 million deaths occurred.[@b1-ott-9-1151],[@b2-ott-9-1151] Aging of the population and adoption of cancer-related lifestyle increased the burden of cancer in developing countries. Reducing the incidence of cancer morbidity was the preferred prevention strategy. New and sensitive biomarkers are urgently required for the detection of high-risk populations and as new strategies for early detection. Currently, the underlying mechanisms of carcinogenesis are poorly understood, and research studies have suggested that environmental factors combined with susceptibility genes may play a critical role in the process.[@b3-ott-9-1151],[@b4-ott-9-1151] Gene polymorphisms, which can decrease the activity of detoxifying carcinogenic substances, may contribute to the transformation of exposure effects.

*PON1* is located on the long arm of chromosome 7. Two important common genetic polymorphisms, PON1-Q192R and PON1-L55M, were identified by the epidemiologic and molecular studies in the coding region of the *PON1* gene at positions 192 and 55. Studies revealed that higher PON1 activity and mRNA levels were related to the PON1-55L allele than to PON1-55M,[@b5-ott-9-1151],[@b6-ott-9-1151] and a decreased stability of the PON1-55M protein may lead to a lower activity of PON1.[@b7-ott-9-1151] In addition, the association between the polymorphism and risk of different cancers, such as prostate cancer[@b8-ott-9-1151] and breast cancer,[@b9-ott-9-1151] was identified by case--control studies, whereas no significant association was identified between the polymorphism and cancer risk in renal cell carcinoma[@b10-ott-9-1151] and ovarian cancer.[@b11-ott-9-1151] Until now, these results remain inconclusive. Therefore, we conducted the present meta-analysis to precisely assess the association between PON1-L55M polymorphism and cancer risk.

Materials and methods
=====================

Search strategy
---------------

We searched the PubMed, Google Scholar, and Web of Science databases for studies published before November 30, 2015, by adopting keywords "cancer OR malignancy OR carcinoma OR tumor OR neoplasm" AND "polymorphism OR mutation OR SNP OR variant" AND "Paraoxonase 1 OR PON1". We also conducted a hand search of references of original articles or reviews on this issue for additional studies. All the eligible studies were restricted to humans. And the articles should be presented in English. We extracted data separately when more than one cancer type or ethnicity was involved in one publication. In addition, we enrolled the report with the largest sample size when more than one report published the same data.

Inclusion criteria and exclusion criteria
-----------------------------------------

We selected studies according to the following criteria: 1) reports that assessed the association between *PON1* polymorphisms and cancer risk; 2) case--control studies only; and 3) publications that could provide the specific genotype frequency of cases and controls directly or indirectly (can be calculated from the article text). Besides, we excluded studies that were: 1) case reports, case-only studies, or reviews; 2) publications without specific genotype frequency of L55M polymorphism in *PON1*; 3) animal studies; and 4) duplicate publications.

Data extraction
---------------

Two investigators (LC and WL) devoted themselves to the data extraction process, and the following details were captured: the name of the first author, year of publication, ethnicity of each population, cancer type, control source, genotyping method, total number of cases and controls, and *P*-value of HWE (Hardy--Weinberg equilibrium). We compared the data and reached consensus for all disagreements by the two investigators.

Statistical analysis
--------------------

We used odds ratio (OR) and 95% confidence interval (CI) to assess the association between PON1-L55M polymorphism and cancer risk. ORs were calculated in five genetic models: allele contrast (M vs L), heterozygote comparison (ML vs LL), homozygote (MM vs LL), recessive (MM vs ML/LL), and dominant (ML/MM vs LL). Between-study heterogeneity was assessed by *χ*^2^-test-based *Q*-statistic test,[@b12-ott-9-1151] and quantified by *I*^2^ values, as well as *P*-values.[@b13-ott-9-1151] No significant heterogeneity was observed when *I*^2^\<50% and *P*\>0.10, and ORs were pooled by a fixed-effects model. Otherwise, the random-effects model was used.[@b14-ott-9-1151] Besides, stratified analyses by ethnicity, cancer type, genotyping method, and control source were performed. We combined any cancer type with less than two studies into the "other cancers" group. In addition, we also divided these cancer types into solid and hematological malignancies, individually. Sensitivity analysis was performed to assess the stability of these findings by removing one single study from the enrolled studies to reveal the influence of individual data sets on the pooled ORs. In the end, Begg's funnel plot and Egger's regression test were performed to assess the publication bias.[@b13-ott-9-1151],[@b15-ott-9-1151] We applied STATA software (version 12.0; StataCorp LP, College Station, TX, USA) to conduct all statistical analyses, and *P*\<0.05 for any tests or genetic models was regarded as statistically significant.

Results
=======

Study characteristics
---------------------

After careful examination according to the inclusion criteria, a total of 21 case--control studies comprising 6,224 cases and 7,014 healthy controls were enrolled in our study ([Table 1](#t1-ott-9-1151){ref-type="table"}).[@b8-ott-9-1151]--[@b11-ott-9-1151],[@b16-ott-9-1151]--[@b32-ott-9-1151] The flow chart of the study selection process is shown in [Figure 1](#f1-ott-9-1151){ref-type="fig"}. Among these studies, three studies were performed in Asians, 14 in Caucasians, and four in mixed group. A total of six cancer types were addressed: four studies on breast cancer; three on prostate cancer; two on colorectal cancer, lung cancer, and ovarian cancer; and eight on other cancers (one study each on acute leukemia, brain tumor, embryonal tumor, hepatocellular carcinoma, lymphohematopoietic cancer, osteosarcoma, renal cell carcinoma, and pancreatic cancer). All genotype frequencies were in HWE with the exception of Antognelli et al[@b16-ott-9-1151] and Ahmed et al,[@b21-ott-9-1151] and these two studies were excluded from the pooled analyses.

Quantitative data synthesis
---------------------------

Significant associations between the PON1-L55M polymorphism and cancer risk were identified in the allele contrast (M vs L: OR =1.221, 95% CI =1.066--1.398, *P*~heterogeneity~=0.000), homozygote (MM vs LL: OR =1.463, 95% CI =1.123--1.905, *P*~heterogeneity~=0.000), heterozygote comparison (ML vs LL: OR =1.161, 95% CI =1.069--1.261, *P*~heterogeneity~=0.162), recessive (MM vs ML/LL: OR =1.381, 95% CI =1.107--1.724, *P*~heterogeneity~=0.000), and dominant (MM/ML vs LL: OR =1.218, 95% CI =1.054--1.407, *P*~heterogeneity~=0.000) models ([Table 2](#t2-ott-9-1151){ref-type="table"}, [Figure 2](#f2-ott-9-1151){ref-type="fig"}).

In stratified analyses by cancer type, the PON1-55M allele was a risk factor for breast cancer in all genetic models (allele contrast: M vs L: OR =2.120, 95% CI =1.066--4.218, *P*~heterogeneity~=0.000; homozygote: MM vs LL: OR =3.666, 95% CI =1.159--11.600, *P*~heterogeneity~=0.000; heterozygote comparison: ML vs LL: OR =1.252, 95% CI =1.020--1.536, *P*~heterogeneity~=0.703; recessive: MM vs ML/LL: OR =3.187, 95% CI =1.052--9.661, *P*~heterogeneity~=0.000; and dominant: MM/ML vs LL: OR =1.887, 95% CI =1.064--3.349, *P*~heterogeneity~=0.001), prostate cancer in the heterozygote comparison model (ML vs LL: OR =1.304, 95% CI =1.049--1.620, *P*~heterogeneity~=0.067), and ovarian cancer in the recessive model (MM vs ML/LL: OR =1.526, 95% CI =1.110--2.097, *P*~heterogeneity~=0.464). Similarly, an increased risk was observed in the Caucasian population (homozygote: MM vs LL: OR =1.461, 95% CI =1.041--2.051, *P*~heterogeneity~=0.000; and heterozygote comparison: ML vs LL: OR =1.170, 95% CI =1.050--1.303, *P*~heterogeneity~=0.185) and the Asian population (allele contrast: M vs L: OR =1.428, 95% CI =1.143--1.784, *P*~heterogeneity~=0.849; homozygote: MM vs LL: OR =2.344, 95% CI =1.304--4.214, *P*~heterogeneity~=0.925; recessive: MM vs ML/LL: OR =2.068, 95% CI =1.175--3.638, *P*~heterogeneity~=0.880; MM/ML vs LL: OR =1.443, 95% CI =1.092--1.907, *P*~heterogeneity~=0.938), and hospital-based group (allele contrast: M vs L: OR =1.303, 95% CI =1.194--1.423, *P*~heterogeneity~=0.062; homozygote: MM vs LL: OR =1.714, 95% CI =1.369--2.147, *P*~heterogeneity~=0.303; heterozygote comparison: ML vs LL: OR =1.293, 95% CI =1.134--1.474, *P*~heterogeneity~=0.139; recessive: MM vs ML/LL: OR =1.484, 95% CI =1.248--1.764, *P*~heterogeneity~=0.510; and dominant: MM/ML vs LL: OR =1.314, 95% CI =1.083--1.594, *P*~heterogeneity~=0.059). In addition, we conducted a stratification analysis by genotyping method, and an increased risk for the PCR-RFLP (polymerase chain reaction-restriction fragment length polymorphism) group was identified ([Table 2](#t2-ott-9-1151){ref-type="table"}). We divided these tumors into solid and hematological tumor groups, and the results of subgroup analyses were not completely consistent with those of overall cancer analyses ([Table 2](#t2-ott-9-1151){ref-type="table"}). We observed an increased risk of solid cancer in the allele contrast, homozygote, heterozygote comparison, and dominant models, and hematological tumor in the allele contrast, homozygote, and recessive models ([Table 2](#t2-ott-9-1151){ref-type="table"}).

Publication bias and sensitivity analysis
-----------------------------------------

Each time, one single study was removed from the enrolled assembly to validate the effect of individual studies on the pooled analysis, and no individual study obviously affected the pooled OR observed ([Figure 3](#f3-ott-9-1151){ref-type="fig"}). Egger's test and Begg's funnel plot were performed to assess the publication bias. The shape of the funnel plot was symmetrical ([Figure 4](#f4-ott-9-1151){ref-type="fig"}). In addition, the results of Egger's test did not show statistical evidence for bias (PON1-L55M MM vs LL: Egger's test: *t*=0.53; *P*=0.604). Thus, no obvious publication bias was found in our meta-analysis, and our results were credible.

Discussion
==========

Previous studies suggested that lifestyle, estrogens, dietary habits, and oxidative and carbonyl stresses potentially play a critical role in the tumorigenesis and progression of cancers.[@b33-ott-9-1151]--[@b35-ott-9-1151] There are several enzyme systems in our body that protect against genotoxic damage, either directly or via free-radical detoxification. Moreover, PON1, which is an antioxidant enzyme, may contribute to the disturbance in antioxidant--oxidant balance.[@b36-ott-9-1151],[@b37-ott-9-1151] Decreased expression of PON1 was identified in lung cancer and pancreatic cancer by previous studies.[@b38-ott-9-1151],[@b39-ott-9-1151] M variants decreased the stability of the PON1 enzyme. Subsequently, the concentration of PON1 in the blood was lowered, which can influence the activity of the enzyme. The LM genotype was identified as having a PON1 activity level between LL and MM genotypes.[@b7-ott-9-1151]

Previous studies suggested that PON1-L55M polymorphism was associated with an increased risk for many cancer types, such as breast and prostate cancers, while a decreased risk was identified in renal cell carcinoma and ovarian cancer. These results were controversial and inconclusive. In our present work, we identified that the PON1-55M allele was associated with an increased risk of cancer. In stratified analyses by cancer type, PON1-L55M polymorphism was a risk factor for breast cancer in all the five genetic models. Previous studies indicated that PON1, which is a part of lipid peroxidation scavenging systems, may affect the cell proliferation and malignant conversion process associated with the development of breast cancer.[@b40-ott-9-1151] In addition, we also observed an increased risk of prostate cancer in the heterozygote comparison model and ovarian cancer in the recessive model. Similarly, an increased risk was observed in the Caucasian population (homozygote and heterozygote comparison models), the Asian population (allele contrast, homozygote, and recessive and dominant models), and the hospital-based group (all the five genetic models). The controls enrolled in our study were not uniformly defined. Some studies adopted the population-based group as the control source, while others adopted the hospital-based group. As a result, once the polymorphism was considered to influence the risk of other diseases, the control source would not always be representative of the underlying source populations. In addition, we observed an increased risk of solid cancer in the allele contrast, homozygote, heterozygote comparison, and dominant models, and hematological tumor in the allele contrast, homozygote, and recessive models. The cause of these differences may be related to the origin of the tumor.

Although we have presented a comprehensive study of the association between PON1-L55M polymorphism and cancer risk, several limitations should be noted. First, a limited number of publications were enrolled in our study and the sample size of each report was relatively small. Second, most of the enrolled publications were Caucasian, and none of them was African. Third, our results were based on single-factor estimates, which may result in a serious confounding bias, for the reason of lack of original data, without adjustment for age, sex, and other risk factors.

To sum up, our study identified that PON1-L55M polymorphism is a risk factor for cancers, particularly breast cancer, prostate cancer, and ovarian cancer. Further well-designed studies with large sample sizes will be continued on this issue of interest.
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![Meta-analysis of the association between PON1-L55M polymorphism and cancer risk in the dominant model (MM/ML vs LL).\
**Note:** Weights are from random effects analysis.\
**Abbreviations:** CI, confidence interval; OR, odds ratio; ID, identification; NA, not available; L allele, leucine; M allele, methionine.](ott-9-1151Fig2){#f2-ott-9-1151}

![Sensitivity analysis of overall OR coefficients for PON1-L55M (MM vs LL).\
**Notes:** Results were calculated by omitting each study in turn. The two ends of the dotted lines represent the 95% CI.\
**Abbreviations:** CI, confidence interval; OR, odds ratio; L allele, leucine; M allele, methionine.](ott-9-1151Fig3){#f3-ott-9-1151}

![Begg's funnel plot of publication bias (homozygote model: MM vs LL).\
**Notes:** Each point represents a separate study for the indicated association. Log(OR), natural logarithm of OR; horizontal line, mean effect size.\
**Abbreviations:** OR, odds ratio; SE, standard error of the mean; L allele, leucine; M allele, methionine.](ott-9-1151Fig4){#f4-ott-9-1151}

###### 

Characteristics of the eligible case--control studies enrolled in the meta-analysis

  First author                                 Year   Ethnicity   Genotyping method   Control source   Cancer type                   Case   Control   Y or N (HWE)                     
  -------------------------------------------- ------ ----------- ------------------- ---------------- ----------------------------- ------ --------- -------------- ----- ----- ----- ---
  Antognelli et al[@b8-ott-9-1151]             2005   Caucasian   PCR-RFLP            H-B              Prostate cancer               67     197       120            43    169   148   Y
  Van Der Logt et al[@b18-ott-9-1151]          2005   Caucasian   PCR-RFLP            P-B              Colorectal cancer             59     166       139            50    162   140   Y
  Stevens et al[@b32-ott-9-1151]               2006   Caucasian   PCR-RFLP            P-B              Breast cancer                 77     230       176            58    223   202   Y
  Stevens et al[@b19-ott-9-1151]               2008   Mixed       TaqMan              P-B              Prostate cancer               165    609       481            189   575   498   Y
  Lurie et al[@b17-ott-9-1151]                 2008   Mixed       TaqMan              P-B              Ovarian cancer                192    65        14             276   145   24    Y
  Arpaci et al[@b11-ott-9-1151]                2009   Caucasian   PCR-RFLP            H-B              Ovarian cancer                5      19        27             2     27    25    Y
  Antognelli et al[@b16-ott-9-1151]            2009   Caucasian   PCR-RFLP            P-B              Breast cancer                 325    115       107            231   125   188   N
  Martinez et al[@b31-ott-9-1151]              2010   Caucasian   TaqMan              H-B              Brain tumor                   30     32        11             88    94    38    Y
  Naidu et al[@b23-ott-9-1151]                 2010   Asian       PCR-RFLP            P-B              Breast cancer                 50     178       159            17    109   126   Y
  Uyar et al[@b10-ott-9-1151]                  2011   Caucasian   PCR-RFLP            P-B              Renal cell carcinoma          6      25        29             10    29    21    Y
  Ergen et al[@b28-ott-9-1151]                 2011   Caucasian   PCR-RFLP            P-B              Osteosarcoma                  3      23        24             9     20    21    Y
  Aksoy-Sagirli et al[@b26-ott-9-1151]         2011   Caucasian   PCR-RFLP            H-B              Lung cancer                   10     94        119            14    102   118   Y
  Hussein et al[@b9-ott-9-1151]                2011   Caucasian   PCR-RFLP            P-B              Breast cancer                 60     21        19             6     23    35    Y
  Vecka et al[@b27-ott-9-1151]                 2012   Caucasian   PCR-RFLP            H-B              Pancreatic cancer             10     39        24             8     37    28    Y
  Kokouva et al[@b30-ott-9-1151]               2013   Caucasian   PCR-RFLP            H-B              Lymphohematopoietic cancers   60     139       117            50    159   142   Y
  de Aguiar Goncalves et al[@b25-ott-9-1151]   2012   Mixed       TaqMan              H-B              Acute leukemia                34     99        104            19    75    131   Y
  Wang et al[@b20-ott-9-1151]                  2012   Asian       PCR-RFLP            P-B              Lung cancer                   2      47        307            0     18    166   Y
  Akkiz et al[@b22-ott-9-1151]                 2013   Caucasian   PCR-RFLP            P-B              Hepatocellular carcinoma      31     81        105            27    89    101   Y
  Antognelli et al[@b24-ott-9-1151]            2013   Caucasian   PCR-RFLP            H-B              Prostate cancer               100    291       180            131   540   497   Y
  Vasconcelos et al[@b29-ott-9-1151]           2014   Mixed       TaqMan              P-B              Embryonal tumor               15     56        85             25    134   177   Y
  Ahmed et al[@b21-ott-9-1151]                 2015   Asian       PCR-RFLP            P-B              Colorectal cancer             2      10        38             16    24    40    N

**Abbreviations:** PCR-RFLP, polymerase chain reaction-restriction fragment length polymorphism; HWE, Hardy--Weinberg equilibrium; Y, polymorphisms conformed to HWE in the control group; N, polymorphisms did not conform to HWE in the control group; H-B, hospital based; P-B, population based; L allele, leucine; M allele, methionine.

###### 

Results of meta-analysis for PON1-L55M polymorphism and cancer risk

  Variables              Case/control   M vs L                                                            MM vs LL   ML vs LL   ML + MM vs LL                                                      MM vs ML + LL                                                                                                                                                                                                                                                      
  ---------------------- -------------- ----------------------------------------------------------------- ---------- ---------- ------------------------------------------------------------------ --------------- ------ ----------------------------------------------------------------- ------- ------ ----------------------------------------------------------------- ------- ------ ----------------------------------------------------------------- ------- ------
  Total                  5,627/6,390    1.221 (1.066--1.398)[\*](#tfn4-ott-9-1151){ref-type="table-fn"}   0.000      79.5       1.463 (1.123--1.905)[\*](#tfn4-ott-9-1151){ref-type="table-fn"}    0.000           72.1   1.161 (1.069--1.261)[\*](#tfn4-ott-9-1151){ref-type="table-fn"}   0.162   24.4   1.218 (1.054--1.407)[\*](#tfn4-ott-9-1151){ref-type="table-fn"}   0.000   62.9   1.381 (1.107--1.724)[\*](#tfn4-ott-9-1151){ref-type="table-fn"}   0.000   69.0
   Prostate cancer       2,210/2,790    1.244 (0.949--1.631)                                              0.000      89.6       1.521 (0.832--2.778)                                               0.000           90.3   1.258 (1.111--1.423)[\*](#tfn4-ott-9-1151){ref-type="table-fn"}   0.067   63.0   1.357 (0.999--1.842)                                              0.003   83.1   1.293 (0.803--2.082)                                              0.000   87.0
   Breast cancer         970/799        2.120 (1.066--4.218)[\*](#tfn4-ott-9-1151){ref-type="table-fn"}   0.000      94.7       3.666 (1.159--11.600)[\*](#tfn4-ott-9-1151){ref-type="table-fn"}   0.000           90.3   1.252 (1.020--1.536)[\*](#tfn4-ott-9-1151){ref-type="table-fn"}   0.703   0.0    1.887 (1.064--3.349)[\*](#tfn4-ott-9-1151){ref-type="table-fn"}   0.001   85.4   3.187 (1.052--9.661)[\*](#tfn4-ott-9-1151){ref-type="table-fn"}   0.000   90.7
   Ovarian cancer        322/499        1.268 (0.988--1.628)                                              0.366      0.0        1.305 (0.691--2.465)                                               0.484           0.0    0.713 (0.418--1.216)                                              0.764   0.0    0.913 (0.550--1.517)                                              0.551   0.0    1.523 (1.107--2.094)[\*](#tfn4-ott-9-1151){ref-type="table-fn"}   0.464   0.0
   Lung cancer           579/418        1.095 (0.666--1.801)                                              0.104      62.2       0.781 (0.344--1.771)                                               0.404           0.0    1.047 (0.766--1.433)                                              0.215   34.8   1.089 (0.670--1.767)                                              0.146   52.7   0.806 (0.361--1.799)                                              0.432   0.0
   Other cancers         1,182/1,532    1.072 (0.894--1.285)                                              0.035      53.5       1.249 (0.626--2.492)                                               0.124           38.3   1.062 (0.896--1.258)                                              0.268   20.3   1.082 (0.864--1.356)                                              0.098   42.1   1.219 (0.978--1.519)                                              0.265   20.7
  Cancer type 2                                                                                                                                                                                                                                                                                                                                                                                                                                                       
   Solid tumor           5,074/5,814    1.201 (1.035--1.395)[\*](#tfn4-ott-9-1151){ref-type="table-fn"}   0.000      80.8       1.420 (1.055--1.911)[\*](#tfn4-ott-9-1151){ref-type="table-fn"}    0.000           74.2   1.148 (1.052--1.253)[\*](#tfn4-ott-9-1151){ref-type="table-fn"}   0.208   21.1   1.191 (1.017--1.394)[\*](#tfn4-ott-9-1151){ref-type="table-fn"}   0.000   63.8   1.356 (1.058--1.739)                                              0.000   71.7
   Hematological tumor   553/576        1.336 (1.123--1.590)[\*](#tfn4-ott-9-1151){ref-type="table-fn"}   0.089      65.3       1.717 (1.134--2.600)[\*](#tfn4-ott-9-1151){ref-type="table-fn"}    0.262           20.6   1.280 (0.992--1.651)                                              0.089   65.4   1.419 (0.928--2.168)                                              0.079   67.6   1.531 (1.092--2.146)[\*](#tfn4-ott-9-1151){ref-type="table-fn"}   0.493   0.0
  Ethnicity                                                                                                                                                                                                                                                                                                                                                                                                                                                           
   Caucasian             2,965/3,686    1.199 (0.993--1.447)                                              0.000      82.2       1.461 (1.041--2.051)[\*](#tfn4-ott-9-1151){ref-type="table-fn"}    0.000           72.9   1.170 (1.050--1.303)[\*](#tfn4-ott-9-1151){ref-type="table-fn"}   0.185   25.6   1.199 (0.981--1.466)                                              0.000   67.7   1.371 (1.025--1.833)                                              0.000   69.4
   Asian                 743/436        1.428 (1.143--1.784)[\*](#tfn4-ott-9-1151){ref-type="table-fn"}   0.849      0.0        2.344 (1.304--4.214)[\*](#tfn4-ott-9-1151){ref-type="table-fn"}    0.925           0.0    1.324 (0.992--1.767)                                              0.797   0.0    1.443 (1.092--1.907)[\*](#tfn4-ott-9-1151){ref-type="table-fn"}   0.938   0.0    2.068 (1.175--3.638)[\*](#tfn4-ott-9-1151){ref-type="table-fn"}   0.880   0.0
   Mixed                 1,919/2,268    1.193 (0.938--1.518)                                              0.005      76.7       1.252 (0.818--1.916)                                               0.052           61.1   1.104 (0.842--1.448)                                              0.093   53.3   1.163 (0.878--1.539)                                              0.053   60.9   1.265 (0.859--1.861)                                              0.012   72.7
  Control source                                                                                                                                                                                                                                                                                                                                                                                                                                                      
   Population-based      3,699/3,705    1.221 (0.989--1.509)                                              0.000      85.2       1.374 (0.916--2.061)                                               0.000           78.6   1.082 (0.974--1.203)                                              0.574   0.0    1.162 (0.953--1.417)                                              0.001   65.1   1.376 (0.964--1.966)                                              0.000   79.3
  Hospital-based         1,928/2,685    1.303 (1.194--1.423)[\*](#tfn4-ott-9-1151){ref-type="table-fn"}   0.062      48.0       1.714 (1.369--2.147)[\*](#tfn4-ott-9-1151){ref-type="table-fn"}    0.303           16.2   1.293 (1.134--1.474)[\*](#tfn4-ott-9-1151){ref-type="table-fn"}   0.139   36.3   1.314 (1.083--1.594)[\*](#tfn4-ott-9-1151){ref-type="table-fn"}   0.059   48.6   1.484 (1.248--1.764)[\*](#tfn4-ott-9-1151){ref-type="table-fn"}   0.510   0.0
  Genotyping method                                                                                                                                                                                                                                                                                                                                                                                                                                                   
   PCR-RFLP              3,635/3,902    1.239 (1.039--1.478)[\*](#tfn4-ott-9-1151){ref-type="table-fn"}   0.000      80.9       1.558 (1.119--2.168)[\*](#tfn4-ott-9-1151){ref-type="table-fn"}    0.000           71.3   1.188 (1.073--1.316)[\*](#tfn4-ott-9-1151){ref-type="table-fn"}   0.208   22.6   1.235 (1.030--1.482)[\*](#tfn4-ott-9-1151){ref-type="table-fn"}   0.000   65.7   1.463 (1.097--1.951)                                              0.000   67.0
   TaqMan                1,992/2,488    1.171 (0.956--1.434)                                              0.012      68.9       1.221 (0.861--1.732)                                               0.100           48.6   1.112 (0.967--1.279)                                              0.169   37.9   1.161 (0.912--1.477)                                              0.103   48.0   1.212 (0.886--1.659)                                              0.027   63.6

**Notes:** *I*^2^: 0%--25%, no heterogeneity; 25%--50%, modest heterogeneity; \>50%, high heterogeneity;

*P*-value: *P*-value of *Q* test for heterogeneity test;

statistically significant (*P*\<0.05).

**Abbreviations:** OR, odds ratio; CI, confidence interval; PCR-RFLP, polymerase chain reaction-restriction fragment length polymorphism; L allele, leucine; M allele, methionine.
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